Related Experiment Videos
The subrenal capsule assay (SRCA) and its predictive value in oncology
Annales Chirurgiae Et Gynaecologiae. Supplementum
|January 1, 1985
Summary
The 6-day subrenal capsule assay (SRCA) effectively predicts drug activity in vivo. This simple, economical test system is valuable for preclinical and clinical drug development, even with tumor heterogeneity.
Area of Science:
- Oncology
- Pharmacology
- Experimental Medicine
Background:
- The 6-day subrenal capsule assay (SRCA) has been utilized since 1978 as a predictive in vivo test system.
- The SRCA aims for simplicity and economy in evaluating drug activity.
- Previous studies have accumulated data relevant to the SRCA's predictive capabilities.
Purpose of the Study:
- To review studies and data supporting the 6-day SRCA as a predictive in vivo test system.
- To evaluate the SRCA's utility at both preclinical and clinical drug development levels.
- To address whether host responses create artifacts in tumor size parameters within the SRCA.
Main Methods:
- Review of laboratory and clinical data accumulated since 1978.
- Utilizing normal, immunocompetent mice.
- Employing a simple tumor size parameter for drug activity evaluation within a 6-day timeframe.
Main Results:
- Laboratory and clinical data support the 6-day SRCA as a predictive test system.
- Experimental data demonstrate the sensitivity of tumor xenografts to biological effects in the SRCA.
- SRCA data suggest tumor heterogeneity does not preclude the usefulness of predictive assays.
Conclusions:
- The 6-day SRCA is a validated predictive test system for drug development.
- The assay is effective in evaluating drug activity in vivo with simplicity and economy.
- The SRCA remains useful despite potential challenges like host responses and tumor heterogeneity.